Page 1364 - Small Animal Internal Medicine, 6th Edition

1336 PART XII Oncology

cellular proliferation in osteosarcoma cells from dogs. Am J Vet Kraus KA, et al. Outcome and prognostic indicators in cats under-
Res. 2008;69:1079. going splenectomy for splenic mast cell tumors. J Am Anim Hosp
VetBooks.ir node metastases in dogs with appendicular osteosarcoma: 228 Lejeune A, et al. Aggressive local therapy combined with systemic
Assoc. 2015;51:231.
Hillers KR, et al. Incidence and prognostic importance of lymph
cases (1986-2003). J Am Vet Med Assoc. 2005;226:1364.
chemotherapy provides long-term control in grade II stage 2
LaRue SM, et al. Limb-sparing treatment for osteosarcoma in dogs. canine mast cell tumour: 21 cases (1999-2012). Vet Comp Oncol.
J Am Vet Med Assoc. 1734;195:1989. 2015;13:267.
Lascelles BD, et al. Improved survival associated with postoperative Lepri E, et al. Diagnostic and prognostic features of feline cutane-
wound infection in dogs treated with limb-salvage surgery for ous mast cell tumours: a retrospective analysis of 40 cases. Vet
osteosarcoma. Ann Surg Oncol. 2005;12:1073. Res Commun. 2003;27 Suppl 1:707.
Mason NJ, et al. Immunotherapy with a HER2-targeting Listeria London CA. Kinase dysfunction and kinase inhibitors. Vet Derma-
induces HER2-specific immunity and demonstrates potential tol. 2013;24:181.
therapeutic effects in a Phase I trial in canine osteosarcoma. Clin London CA, et al. Multi-center, placebo-controlled, double-blind,
Cancer Res. 2016;22:4380. randomized study of oral toceranib phosphate (SU11654), a
McMahon M, et al. Adjuvant carboplatin and gemcitabine combi- receptor tyrosine kinase inhibitor, for the treatment of dogs with
nation chemotherapy postamputation in canine appendicular recurrent (either local or distant) mast cell tumor following sur-
osteosarcoma. J Vet Intern Med. 2011;25:511. gical excision. Clin Cancer Res. 2009;15:3856.
Moore AS, et al. Doxorubicin and BAY 12-9566 for the treatment Macy DW, et al. Mast cell tumor. In: Withrow SJ, et al, eds. Clinical
of osteosarcoma in dogs: a randomized, double-blind, placebo- veterinary oncology. Philadelphia: JB Lippincott; 1989.
controlled study. J Vet Intern Med. 2007;21:783. McManus PM. Frequency and severity of mastocythemia in dogs
Mueller F, et al. Palliative radiotherapy with electrons of appendicu- with and without mast cell tumors: 120 cases (1995-1997). J Am
lar osteosarcoma in 54 dogs. In Vivo. 2005;19:713. Vet Med Assoc. 1999;215:355.
O’Brien MG, et al. Resection of pulmonary metastases in canine Melville K, et al. Feline cutaneous mast cell tumours: a UK-based
osteosarcoma: 36 cases. Vet Surg. 1993;22:105. study comparing signalment and histological features with long-
Rosenberger JA, Pablo NV, Crawford PC. Prevalence of and intrin- term outcomes. J Feline Med Surg. 2015;17:486.
sic risk factors for appendicular osteosarcoma in dogs: 179 cases Mochizuki H, et al. Association of breed and histopathological
(1996-2005). J Am Vet Med Assoc. 2007;231:1076. grade in canine mast cell tumours. Vet Comp Oncol. 2017;15:829.
Rowell JL, McCarthy DO, Alvarez CE. Dog models of naturally Molander-McCrary H, et al. Cutaneous mast cell tumors in cats: 32
occurring cancer. Trends Mol Med. 2011;17:380. cases (1991-1994). J Am Anim Hosp Assoc. 1998;34:281.
Rubin JA, et al. Factors associated with pathological fractures in Pryer NK, et al. Proof of target for SU11654: inhibition of KIT
dogs with appendicular primary bone neoplasia: 84 cases phosphorylation in canine mast cell tumors. Clin Cancer Res.
(2007-2013). J Am Vet Med Assoc. 2015;247:917. 2003;9:5729.
Sabattini S, et al. Comparative assessment of the accuracy of cyto- Romansik EM, et al. Mitotic index is predictive for survival for
logic and histologic biopsies in the diagnosis of canine bone canine cutaneous mast cell tumors. Vet Pathol. 2007;44:335.
lesions. J Vet Intern Med. 2017;31:864. Séguin B, et al. Clinical outcome of dogs with grade-II mast cell
Selmic LE, et al. Outcome and prognostic factors for osteosarcoma tumors treated with surgery alone: 55 cases (1996-1999). J Am
of the maxilla, mandible, or calvarium in dogs: 183 cases Vet Med Assoc. 2001;218:1120.
(1986-2012). J Am Vet Med Assoc. 2014;245:930. Sledge DG, et al. Canine cutaneous mast cell tumors: a combined
Mast Cell Tumors clinical and pathologic approach to diagnosis, prognosis, and
Barrett LE, et al. Outcome following treatment of feline gastro- treatment selection. Vet J. 2016;215:43.
intestinal mast cell tumours. Vet Comp Oncol. 2018;16:188. Stefanello D, et al. Comparison of 2- and 3-category histologic
Camus MS, et al. Cytologic criteria for mast cell tumor grading in grading systems for predicting the presence of metastasis at the
dogs with evaluation of clinical outcome. Vet Pathol. 2016;53:1117. time of initial evaluation in dogs with cutaneous mast cell
Carlsten KS, et al. Multicenter prospective trial of hypofractionated tumors: 386 cases (2009-2014). J Am Vet Med Assoc. 2015;246:765.
radiation treatment, toceranib, and prednisone for measurable Thompson JJ, et al. Canine subcutaneous mast cell tumor: charac-
canine mast cell tumors. J Vet Intern Med. 2012;26:135. terization and prognostic indices. Vet Pathol. 2011;48:156.
Evans BJ, et al. Treatment outcomes and prognostic factors of feline Webster JD, et al. Cellular proliferation in canine cutaneous mast
splenic mast cell tumors: a multi-institutional retrospective study cell tumors: associations with c-KIT and its role in prognostica-
of 64 cases. Vet Comp Oncol. 2018;16:20. tion. Vet Pathol. 2007;44:3.
Hahn KA, et al. Masitinib is safe and effective for the treatment of Injection Site Sarcomas
canine mast cell tumors. J Vet Intern Med. 2008;22:1301. Barber L, et al. Combined doxorubicin and cyclophosphamide che-
Henry C, Herrera C. Mast cell tumors in cats: clinical update and motherapy for nonresectable feline fibrosarcoma. J Am Anim
possible new treatment avenues. J Feline Med Surg. 2013;15:41. Hosp Assoc. 2000;36:416.
Hosoya K, et al. Adjuvant CCNU (lomustine) and prednisone che- Hershey AE, et al. Prognosis for presumed feline vaccine-associated
motherapy for dogs with incompletely resected grade 2 mast cell sarcoma after excision: 61 cases (1986-1996). J Am Vet Med
tumors. J Am Anim Hosp Assoc. 2009;45:14. Assoc. 2000;216:58.
Jones CL, et al. Detection of c-kit mutations in canine mast cell Holtermann N, et al. The tyrosine kinase inhibitor toceranib in
tumors using fluorescent polyacrylamide gel electrophoresis. J feline injection site sarcoma: efficacy and side effects. Vet Comp
Vet Diagn Invest. 2004;16:95. Oncol. 2017;15:632.
Kiupel M, et al. Proposal of a 2-tier histologic grading system for Kass PH, et al. Epidemiologic evidence for a causal relation between
canine cutaneous mast cell tumors to more accurately predict vaccination and fibrosarcoma tumorigenesis in cats. J Am Vet
biological behavior. Vet Pathol. 2011;48:147. Med Assoc. 1993;203:396.